The place of metoprolol tartrate in the treatment of cardiovascular diseases
| Autor: | N. V. Romanova, I. V. Zhirov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Медицинский совет, Vol 0, Iss 4, Pp 16-19 (2016) |
| Druh dokumentu: | article |
| ISSN: | 2079-701X 2658-5790 |
| DOI: | 10.21518/2079-701X-2016-4-16-19 |
| Popis: | Since the beginning of the 1960s, beta-blockers have been number one medications in the treatment of cardiovascular diseases. A number of randomized controlled trials (RCTs) demonstrated positive effect of beta-blockers on morbidity and mortality [1]. It is difficult to overestimate the role of beta-blockers in modern cardiology. According to the results of a meta-analysis of 18 RCTs, administration of beta-blockers in patients with a risk of cardiovascular disease was associated with a reduction of the risk of stroke by 29%, coronary heart disease (CHD) by 7%, and chronic heart failure (CHF) by 29% [2]. In combination with ACE inhibitors, antiplatelet agents and statins, beta blockers helped to decrease mortality from acute coronary syndrome by 90% [3]. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|